Evaluation of the Association of IGF2BP2 Variants With Type 2 Diabetes in French Caucasians

  1. Konsta Duesing1,
  2. Ghazaleh Fatemifar1,
  3. Guillaume Charpentier2,
  4. Michel Marre34,
  5. Jean Tichet5,
  6. Serge Hercberg6,
  7. Beverley Balkau78,
  8. Philippe Froguel19 and
  9. Fernando Gibson1
  1. 1Section of Genomic Medicine, Imperial College London, Hammersmith Campus, London, U.K
  2. 2Endocrinology-Diabetology Unit, Corbeil Hospital, Corbeil, France
  3. 3Endocrinology-Diabetology Unit, Bichat Hospital, Paris, France
  4. 4INSERM U695, Paris, France
  5. 5Institut Régional Pour la Santé, Tours, France
  6. 6INSERM U557/U1125 Inra/Cnam/University Paris, Bobigny, France
  7. 7INSERM U780-IFR69, Villejuif, France
  8. 8Paris Univ-Sud, Orsay, France
  9. 9CNRS 8090, Institut de Biologie de Lille, Institut Pasteur, Lille, France
  1. Corresponding author: Fernando Gibson, fernando.gibson{at}imperial.ac.uk

Abstract

OBJECTIVE—We performed a comprehensive genetic association study of common variation spanning the IGF2BP2 locus in order to replicate the association of the “confirmed” type 2 diabetes susceptibility variants rs4402960 and rs1470579 in the French Caucasian population and to further characterize the susceptibility variants at this novel locus.

RESEARCH DESIGN AND METHODS—We genotyped a total of 21 tagging single nucleotide polymorphisms spanning the IGF2BP2 locus in our type 2 diabetes case-control cohort comprising 3,093 French Caucasian subjects.

RESULTS—IGF2BP2 variants rs4402960 and rs1470579 were not associated with type 2 diabetes in the present study (P = 0.632 and P = 0.896, respectively). Meta-analysis of genotype data from over 34,000 subjects demonstrated that our inability to replicate rs4402960/rs1470579 was consistent with the findings from several previous genome-wide association study (GWAS) datasets that were underpowered to detect this modest association signal (odds ratio [OR] 1.14). We obtained novel evidence that rs9826022, a borderline rare variant (5% minor allele frequency) in the 3′ downstream region, was associated with type 2 diabetes (P = 0.0002; OR 1.53 [95% CI 1.22–1.91]). This result was corroborated by the meta-analysis of 10,542 genotypes from the current study and GWAS datasets using both fixed (P = 9.47 × 10−6; 1.30 [1.16–1.46]) and random effects (P = 0.001; 1.30 [1.11–1.52)] calculations.

CONCLUSIONS—We were unable to replicate the confirmed rs4402960/rs1470579 susceptibility variants but found novel evidence for a rare variant in the 3′ downstream region of IGF2BP2. Further genetic and functional studies are required to identify the etiological IGF2BP2 variants.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 22 April 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit,and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted April 17, 2008.
    • Received December 17, 2007.
« Previous | Next Article »Table of Contents